CHF 1535 versus high-dose beclometasone and Seretide in severe asthma

Phase 3, randomised, triple-blind trial in asthma comparing CHF 1535 combination arm, High-dose beclometasone dipropionate monotherapy arm and Seretide active comparator arm (3 arms). Primary endpoints: Change from baseline in pre-dose morning FEV1 measured at clinic and Change from baseline in percentage of complete days without asthma symptoms. Started Aug 2007; status: completed.